
John M. Hoffmann
Examiner (ID: 5190, Phone: (571)272-1191 , Office: P/1741 )
| Most Active Art Unit | 1731 |
| Art Unit(s) | 1712, 1731, 1741, 1791, 1304, 1303 |
| Total Applications | 1565 |
| Issued Applications | 722 |
| Pending Applications | 142 |
| Abandoned Applications | 703 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17292260
[patent_doc_number] => 20210388099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => METHOD FOR TREATING MULTIPLE SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 17/203671
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57608
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203671
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203671 | METHOD FOR TREATING MULTIPLE SCLEROSIS | Mar 15, 2021 | Abandoned |
Array
(
[id] => 18486177
[patent_doc_number] => 20230213519
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/911819
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911819
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911819 | DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS | Mar 14, 2021 | Abandoned |
Array
(
[id] => 16855158
[patent_doc_number] => 20210155903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => Combination Therapy
[patent_app_type] => utility
[patent_app_number] => 17/168551
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29465
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168551
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/168551 | Combination Therapy | Feb 4, 2021 | Abandoned |
Array
(
[id] => 18272436
[patent_doc_number] => 20230093678
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => PEPTIDE IMMUNOGENS TARGETING PCSK9 AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF PCSK9-MEDIATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/795734
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22684
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17795734
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/795734 | PEPTIDE IMMUNOGENS TARGETING PCSK9 AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF PCSK9-MEDIATED DISORDERS | Jan 27, 2021 | Abandoned |
Array
(
[id] => 16991885
[patent_doc_number] => 20210230305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/154304
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15565
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154304
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/154304 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | Jan 20, 2021 | Abandoned |
Array
(
[id] => 17140229
[patent_doc_number] => 20210308240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/147244
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147244
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/147244 | POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY | Jan 11, 2021 | Abandoned |
Array
(
[id] => 18341908
[patent_doc_number] => 11639382
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-02
[patent_title] => Antibodies specific for sulfation sites of Wnt pathway proteins
[patent_app_type] => utility
[patent_app_number] => 17/130049
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 17159
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130049
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130049 | Antibodies specific for sulfation sites of Wnt pathway proteins | Dec 21, 2020 | Issued |
Array
(
[id] => 16807940
[patent_doc_number] => 20210130493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => MEDICAMENT COMPRISING ANTI-PHOSPHOLIPASE D4 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/127202
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127202 | MEDICAMENT COMPRISING ANTI-PHOSPHOLIPASE D4 ANTIBODY | Dec 17, 2020 | Abandoned |
Array
(
[id] => 18109630
[patent_doc_number] => 20230002510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => CELA-1 INHIBITION FOR TREATMENT OF LUNG DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/778188
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778188 | CELA-1 INHIBITION FOR TREATMENT OF LUNG DISEASE | Nov 22, 2020 | Abandoned |
Array
(
[id] => 19043787
[patent_doc_number] => 11932873
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Reducing immune tolerance induced by PD-L1
[patent_app_type] => utility
[patent_app_number] => 17/101780
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 13885
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101780
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/101780 | Reducing immune tolerance induced by PD-L1 | Nov 22, 2020 | Issued |
Array
(
[id] => 18675161
[patent_doc_number] => 20230312750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => ANTI-PCSK9 ANTIBODY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/776295
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8314
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776295 | ANTI-PCSK9 ANTIBODY AND USE THEREOF | Nov 17, 2020 | Abandoned |
Array
(
[id] => 20699747
[patent_doc_number] => 12622431
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-12
[patent_title] => Insect control nanobodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/775898
[patent_app_country] => US
[patent_app_date] => 2020-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 34
[patent_no_of_words] => 26096
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/775898 | Insect control nanobodies and uses thereof | Nov 10, 2020 | Issued |
Array
(
[id] => 16657455
[patent_doc_number] => 20210054091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => ANTIBODIES TO CD40
[patent_app_type] => utility
[patent_app_number] => 17/091375
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/091375 | ANTIBODIES TO CD40 | Nov 5, 2020 | Abandoned |
Array
(
[id] => 18184982
[patent_doc_number] => 20230045712
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/775143
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25033
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775143
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/775143 | ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nov 5, 2020 | Pending |
Array
(
[id] => 16658677
[patent_doc_number] => 20210055314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => METHOD FOR DETECTING TOTAL 25-HYDROXYVITAMIN D USING ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3
[patent_app_type] => utility
[patent_app_number] => 17/087914
[patent_app_country] => US
[patent_app_date] => 2020-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22053
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17087914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/087914 | Antibodies to 25-hydroxyvitamin D2 and D3 | Nov 2, 2020 | Issued |
Array
(
[id] => 18497471
[patent_doc_number] => 20230220112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => ANTIBODIES FOR BINDING PLASMIN
[patent_app_type] => utility
[patent_app_number] => 17/772090
[patent_app_country] => US
[patent_app_date] => 2020-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772090 | ANTIBODIES FOR BINDING PLASMIN | Oct 27, 2020 | Pending |
Array
(
[id] => 19165842
[patent_doc_number] => 11981730
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Anti-CXCL13 antibodies and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 17/030627
[patent_app_country] => US
[patent_app_date] => 2020-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 55
[patent_no_of_words] => 37630
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030627
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/030627 | Anti-CXCL13 antibodies and methods of using the same | Sep 23, 2020 | Issued |
Array
(
[id] => 19922989
[patent_doc_number] => 12297260
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => DKK1 antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/015212
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 33516
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015212
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/015212 | DKK1 antibodies and methods of use | Sep 8, 2020 | Issued |
Array
(
[id] => 16628781
[patent_doc_number] => 20210047434
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/011433
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79880
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011433
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011433 | METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS | Sep 2, 2020 | Pending |
Array
(
[id] => 16720146
[patent_doc_number] => 20210087293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
[patent_app_type] => utility
[patent_app_number] => 17/010354
[patent_app_country] => US
[patent_app_date] => 2020-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010354
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/010354 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | Sep 1, 2020 | Issued |